Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 -- Roivant announced today the completion of the previously announced acquisition by Roche of Telavant, for an upfront payment of...